Literature DB >> 1823342

Flow cytometric analysis of antineoplastic effects of interferon-alpha, beta and gamma labelled with fluorescein isothiocyanate on cultured brain tumors.

Y Numa1, K Kawamoto, N Sakai, H Matsumura.   

Abstract

Antineoplastic effects of interferons (IFNs) on brain tumors have often been reported in the literature, however, so far as we know, there are no reports of the study on the antineoplastic effect of IFNs (alpha, beta, and gamma) labelled with fluorescein isothiocyanate (FITC) using flow cytometry (FCM). Three established glioma cell lines and 11 cultured cells of brain tumor from surgical specimens were exposed to IFN-alpha, beta, and gamma at the concentrations of 10(2)-10(5) IU/ml for 24 h, respectively. Using FCM, the viability of the cells was evaluated with fluorescein diacetate stain and the cell cycle was analyzed from the DNA-histogram with propidium iodide stain. Furthermore, FITC-labelled IFN-alpha, beta and gamma were also contacted with each cell to calculate respective positive cells. The viability decreased about 60% on day 1 and day 3, indicating the effect of IFN-alpha and beta on U373MG cells and on some cultured glioma cells from surgical materials, whereas, IFN-gamma had no effects. Antineoplastic effect of each IFN well correlated with FITC-positive rates, demonstrating S phase block in the cell cycle. IFN-gamma had no antineoplastic effects, whereas IFN-alpha and beta showed antineoplastic effects, which fact suggested that IFN-gamma receptor be different from those of IFN-alpha and beta. The method of FITC-labelling for IFNs with the aid of FCM has the advantages as follows: 1) Antineoplasticity of IFN can be simply evaluated with FCM; 2) It is easy to analyze the action mechanism of IFN; 3) Information on the receptor is obtainable; and 4) Sensitivity can be evaluated prior to administration of IFN, suggesting possibilities of clinical application of this method.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1823342     DOI: 10.1007/BF00165530

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  [Interaction of human fibroblast interferon with chemotherapeutic agents and radiation of human gliomas in nude mice].

Authors:  O Nakamura; K Maruo; Y Ueyama; K Nomura; K Takakura
Journal:  Neurol Med Chir (Tokyo)       Date:  1986-09       Impact factor: 1.742

2.  Inhibition by interferon preparations of a solid malignant tumour and pulmonary metastasis in mice.

Authors:  I Gresser; C Bourali-Maury
Journal:  Nat New Biol       Date:  1972-03-22

3.  Binding of human interferon alpha to cells of different sensitivities: studies with internally radiolabeled interferon retaining full biological activity.

Authors:  S Yonehara; M Yonehara-Takahashi; A Ishii
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

4.  Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon.

Authors:  J E Blalock; J A Georgiades; M P Langford; H M Johnson
Journal:  Cell Immunol       Date:  1980-02       Impact factor: 4.868

5.  [Interferon and its implication for malignant brain tumor].

Authors:  N Shitara; K Takakura; K Sano
Journal:  No Shinkei Geka       Date:  1979-07

6.  Effect of interferon on growth and division cycle of Friend erythroleukemic murine cells in vitro.

Authors:  G P Matarese; G B Rossi
Journal:  J Cell Biol       Date:  1977-11       Impact factor: 10.539

7.  Discrimination between nonmalignant and malignant cells by combinations of IFN-gamma and IFN-alpha/beta.

Authors:  W R Fleischmann; R C Newton; C M Fleischmann; N H Colburn; M M Brysk
Journal:  J Biol Response Mod       Date:  1984-08

8.  [Interferon therapy for brain tumor patients (author's transl)].

Authors:  S Ueda; K Hirakawa; K Suzuki; Y Nakagawa; N Ibayashi; T Kishida
Journal:  No Shinkei Geka       Date:  1982-02-10

9.  Potentiation of the direct anticellular activity of mouse interferons: mutual synergism and interferon concentration dependence.

Authors:  W R Fleischmann
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

10.  Clinical evaluation for the mechanism of cisplatin with bromodeoxyuridine by flow cytometry and clinico-histological study.

Authors:  Y Wada; K Kawamoto; S Oka; T Yamashita; T Kumazawa; H Matsumura
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

View more
  2 in total

1.  Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines.

Authors:  J I Garrison; M E Berens; J R Shapiro; S Treasurywala; G Floyd-Smith
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

2.  Interferon effect on glycosaminoglycans in mouse glioma in vitro.

Authors:  M Wiranowska; A K Naidu
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.